The Biostatistics Shared Resource provides support for the three broad major programmatic areas of YCC: clinical science;basic science;and population science. The services provided include: biostatistical support to research projects, assistance with the statistical and research aspects of new research projects and grant applications, data analysis, and training/As such, this core is vital to clinical trials/study design process. Additionally, this core has the major responsibility to support the protocol review and monitoring process of the YCC. Thus, this Shared Resource provides critical support for the complete spectrum of statistical services, from study design through the final research report writing. In late 2005, Dr. Theodore Holford accepted the position as Director of this core facility. Dr. Holford will work closely with Dr. Daniel Zelterman, who serves as Co-Director of the Biostatistics Shared Resource. The Biostatistics Shared Resource is Cancer Center Managed and provides statistical support and data analysis to YCC in the form of active consultation with six Ph.D. statisticians dedicated to the YCC. The 2 major criticisms of the previous renewal have been addressed. Specifically, creation of a Biostatistics Clinical Studies Group, chaired by Dr. Holford, ensures that biostatistical expertise applied to Protocol Review Committee evaluation of prospective clinical trials will be completely distinct from that involved in the particular study's design and subsequent analysis of accrued data. In addition, the biostatistical staff has been significantly expanded, to provide full coverage for the marked increase in investigator-initiated clinical research activities, resulting from the recruitment of a large number of new clinical researchers. Over the past 2 years, 11 new investigative clinical oncologists have joined the YCC, and their clinical trials efforts have led to a 56% increase in the required biostatistical support. In order to support these increased needs, the faculty biostatistician staff of this Shared Resource has grown from 2 to 7. In this renewal application, we are requesting 1.75 FTE for the next period of funding. In 2005 100%, or 42, users were YCC members (65.5% Peer reviewed) from all 8 of the YCC research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-31
Application #
7916705
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
31
Fiscal Year
2009
Total Cost
$178,360
Indirect Cost
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Wang, Shi-Yi; Hsu, Sylvia H; Huang, Siwan et al. (2018) Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End-of-Life Care. Health Serv Res 53:4291-4309
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Liu, Huafeng; Li, Xin; Hu, Li et al. (2018) A crucial role of the PD-1H coinhibitory receptor in suppressing experimental asthma. Cell Mol Immunol 15:838-845
Altwerger, Gary; Bonazzoli, Elena; Bellone, Stefania et al. (2018) In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers. Mol Cancer Ther 17:1003-1011
Sanmamed, Miguel F; Chen, Lieping (2018) A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell 175:313-326
Gupta, Swati; Mani, Navin R; Carvajal-Hausdorf, Daniel E et al. (2018) Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Lab Invest 98:1076-1083
Bellone, Stefania; Buza, Natalia; Choi, Jungmin et al. (2018) Exceptional Response to Pembrolizumab in a Metastatic, Chemotherapy/Radiation-Resistant Ovarian Cancer Patient Harboring a PD-L1-Genetic Rearrangement. Clin Cancer Res 24:3282-3291
Altan, Mehmet; Kidwell, Kelley M; Pelekanou, Vasiliki et al. (2018) Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. NPJ Breast Cancer 4:40
Kim, Tae Kon; Herbst, Roy S; Chen, Lieping (2018) Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. Trends Immunol 39:624-631
Goldberg, Sarah B; Patel, Abhijit A (2018) Monitoring immunotherapy outcomes with circulating tumor DNA. Immunotherapy 10:1023-1025

Showing the most recent 10 out of 675 publications